Fintel reports that on December 30, 2024, HC Wainwright & Co. initiated coverage of NewAmsterdam Pharma Company N.V.

Investment analysts at HC Wainwright initiated coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a ...

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) major shareholder Nap B.V. Forgrowth sold 25,132 shares of the firm’s ...

H.C. Wainwright analyst Ed Arce initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $48 price target NewAmsterdam is a ...

In the preceding three months, 6 analysts have released ratings for NewAmsterdam Pharma (NASDAQ:NAMS), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late ...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) just reported positive results the other day from its phase 3 BROADWAY study using obicetrapib for the treatment of patients with Atherosclerotic ...

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late ...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is emerging as a significant player in the cardiovascular disease treatment landscape, with its lead drug candidate obicetrapib garnering attention from ...

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted. Drugmakers to raise US prices on over 250 medicines starting ...